A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

By sjmartinez • February 25, 2025

Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K. A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC. Future Oncol. 2025 Feb 24:1-13. doi: 10.1080/14796694.2025.2463880. Epub ahead of print. PMID: 39995095.

Tags: Hematology/Oncology, Publications

Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis

Britten K, Lipsyc-Sharf M, Yang EH, McCloskey S, Sedrak MS, Teshome M, LaBarbera J, Bardia A, McAndrew N. Socioeconomic disparities in long-term heart failure risk[...]

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations

Napolitano A, Joensuu H, Rothschild S, Evans D, Heinrich MC, Sutton TL, Mayo SC, Boye K, Falkenhorst J, Le Cesne A, Hohenberger P, Rutkowski P,[...]

Cardiotoxicity of T cell immunotherapies

Raddatz MA, Stein-Merlob AF, Mahmood SS, Ganatra S, Addison D, Lin TL, Larson SM, Yang EH. Cardiotoxicity of T cell immunotherapies. Nat Rev Cardiol. 2026[...]